Crescita Therapeutics Inc. today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023.
LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:
Election of Directors
| Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
| FOR | WITHHELD | FOR | WITHHELD | |
| Daniel N. Chicoine | 4,113,511 | 91,743 | 97.8% | 2.2% |
| Anthony E. Dobranowski | 3,549,815 | 655,439 | 84.4% | 15.6% |
| John C. London | 3,550,494 | 654,760 | 84.4% | 15.6% |
| Deborah Shannon-Trudeau | 4,115,644 | 89,610 | 97.9% | 2.1% |
| Serge Verreault | 3,550,534 | 654,720 | 84.4% | 15.6% |
Appointment of External Auditors
| Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
| FOR | WITHHELD | FOR | WITHHELD | |
| Ernst & Young LLP reappointed | 4,965,906 | 47,466 | 99.1% | 0.9% |
Consideration of a Special Resolution Approving a Change of the Municipality of Crescita’s Registered Office
| Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
| FOR | AGAINST | FOR | AGAINST | |
| Change of municipality approved | 4,181,460 | 23,794 | 99.4% | 0.6% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230621953997/en/
Contacts
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
Linda Kisa, CPA, CA
Email: lkisa@crescitatx.com
Source: Crescita Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20230621953997/en